Skip to main content
SpringerLink
Log in

Monoclonal Antibodies in Cancer Therapy

  • Chapter
General Principles of Tumor Immunotherapy

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol. 2004;113:171–182.

    Article  PubMed  CAS  Google Scholar 

  2. Lin MZ, Teitell MA, Schiller GJ. The evolution of antibodies into versatile tumor-targeting agents. Clin Cancer Res. 2005;11:129–138.

    PubMed  CAS  Google Scholar 

  3. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118–129.

    Article  PubMed  CAS  Google Scholar 

  4. Hunkapiller T, Goverman J, Koop BF, Hood L. Implications of the diversity of the immunoglobulin gene superfamily. Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:15–29.

    PubMed  CAS  Google Scholar 

  5. Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302:575–581.

    Article  PubMed  CAS  Google Scholar 

  6. Presta L. Antibody engineering for therapeutics. Curr Opin Struct Biol. 2003;13:519–525.

    Article  PubMed  CAS  Google Scholar 

  7. Hudson PJ, Souriau C. Engineered antibodies. Nat Med. 2003;9:129–134.

    Article  PubMed  CAS  Google Scholar 

  8. Cao Y, Lam L. Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev. 2003;55:171–197.

    Article  PubMed  CAS  Google Scholar 

  9. Kufer P, Lutterbuse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol. 2004;22:238–244.

    Article  PubMed  CAS  Google Scholar 

  10. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol. 1997;9:717–722.

    Article  PubMed  CAS  Google Scholar 

  11. Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology. 2002;63 Suppl 1:17–24.

    Article  PubMed  CAS  Google Scholar 

  12. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671–680.

    PubMed  CAS  Google Scholar 

  13. Tarli L, Balza E, Viti F, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood. 1999;94:192–198.

    PubMed  CAS  Google Scholar 

  14. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood. 1998;92:1184–1190.

    PubMed  CAS  Google Scholar 

  15. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol. 1999;11:541–547.

    Article  PubMed  CAS  Google Scholar 

  16. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003;95:851–867.

    Article  PubMed  Google Scholar 

  17. Besnault L, Schrantz N, Auffredou MT, Leca G, Bourgeade MF, Vazquez A. B cell receptor cross-linking triggers a caspase-8-dependent apoptotic pathway that is independent of the death effector domain of Fas-associated death domain protein. J Immunol. 2001;167:733–740.

    PubMed  CAS  Google Scholar 

  18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443–446.

    Article  PubMed  CAS  Google Scholar 

  19. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23:474–481.

    Article  PubMed  CAS  Google Scholar 

  20. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738–2743.

    Article  PubMed  CAS  Google Scholar 

  21. King DM, Albertini MR, Schalch H, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004;22:4463–4473.

    Article  PubMed  CAS  Google Scholar 

  22. Pastan II, Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev. 1998;31:53–88.

    Article  PubMed  Google Scholar 

  23. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241–247.

    Article  PubMed  CAS  Google Scholar 

  24. Bagshawe KD, Sharma SK, Begent RH. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther. 2004;4:1777–1789.

    Article  PubMed  CAS  Google Scholar 

  25. Rader C. Antibody libraries in drug and target discovery. Drug Discov Today. 2001;6:36–43.

    Article  PubMed  CAS  Google Scholar 

  26. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.

    Article  PubMed  CAS  Google Scholar 

  27. Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov. 2003;2:693–694.

    Article  PubMed  CAS  Google Scholar 

  28. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315–1317.

    Article  PubMed  CAS  Google Scholar 

  29. Burton DR, Barbas CF, 3rd. Human antibodies from combinatorial libraries. Adv Immunol. 1994;57:191–280.

    Article  PubMed  CAS  Google Scholar 

  30. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433–455.

    Article  PubMed  CAS  Google Scholar 

  31. Lipovsek D, Pluckthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods. 2004;290:51–67.

    Article  PubMed  CAS  Google Scholar 

  32. Feldhaus MJ, Siegel RW. Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods. 2004;290:69–80.

    Article  PubMed  CAS  Google Scholar 

  33. Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci U S A. 1995;92:9348–9352.

    Article  PubMed  CAS  Google Scholar 

  34. Rader C, Barbas CF, 3rd. Phage display of combinatorial antibody libraries. Curr Opin Biotechnol. 1997;8:503–508.

    Article  PubMed  CAS  Google Scholar 

  35. Fellouse FA, Wiesmann C, Sidhu SS. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A. 2004;101:12467–12472.

    Article  PubMed  CAS  Google Scholar 

  36. Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296:57–86.

    Article  PubMed  CAS  Google Scholar 

  37. Vaughan TJ, Williams AJ, Pritchard K, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 1996;14:309–314.

    Article  PubMed  CAS  Google Scholar 

  38. Rader C, Ritter G, Nathan S, et al. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem. 2000;275:13668–13676.

    Article  PubMed  CAS  Google Scholar 

  39. Tsurushita N, Park M, Pakabunto K, et al. Humanization of a chicken anti-IL-12 monoclonal antibody. J Immunol Methods. 2004;295:9–19.

    Article  PubMed  CAS  Google Scholar 

  40. Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol. 2002;13:593–597.

    Article  PubMed  CAS  Google Scholar 

  41. Reisner Y, Dagan S. The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases. Trends Biotechnol. 1998;16:242–246.

    Article  PubMed  CAS  Google Scholar 

  42. Pasqualini R, Arap W. Hybridoma-free generation of monoclonal antibodies. Proc Natl Acad Sci U S A. 2004;101:257–259.

    Article  PubMed  CAS  Google Scholar 

  43. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–1800.

    Article  PubMed  CAS  Google Scholar 

  44. Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: From anti-Tac to Zenapax. Methods. 2005;36:69–83.

    Article  PubMed  CAS  Google Scholar 

  45. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984;81:6851–6855.

    Article  PubMed  CAS  Google Scholar 

  46. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323–327.

    Article  PubMed  CAS  Google Scholar 

  47. Holmes MA, Buss TN, Foote J. Conformational correction mechanisms aiding antigen recognition by a humanized antibody. J Exp Med. 1998;187:479–485.

    Article  PubMed  CAS  Google Scholar 

  48. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. 1992;224:487–499.

    Article  PubMed  CAS  Google Scholar 

  49. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC. Structural insights into the evolution of an antibody combining site. Science. 1997;276:1665–1669.

    Article  PubMed  CAS  Google Scholar 

  50. Rosok MJ, Yelton DE, Harris LJ, et al. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J Biol Chem. 1996;271:22611–22618.

    Article  PubMed  CAS  Google Scholar 

  51. Baca M, Presta LG, O’Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem. 1997;272:10678–10684.

    Article  PubMed  CAS  Google Scholar 

  52. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y). 1994;12:899–903.

    Article  CAS  Google Scholar 

  53. Osbourn J, Groves M, Vaughan T. From rodent reagents to human therapeutics using antibody guided selection. Methods. 2005;36:61–68.

    Article  PubMed  CAS  Google Scholar 

  54. Rader C, Cheresh DA, Barbas CF, 3rd. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci U S A. 1998;95:8910–8915.

    Article  PubMed  CAS  Google Scholar 

  55. Ritter G, Cohen LS, Williams C, Jr., Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 2001;61:6851–6859.

    PubMed  CAS  Google Scholar 

  56. Clark M. Antibody humanization: a case of the ‘Emperor’s new clothes’? Immunol Today. 2000;21:397–402.

    Article  PubMed  CAS  Google Scholar 

  57. Barbas CF, 3rd, Burton DR. Selection and evolution of high-affinity human anti-viral antibodies. Trends Biotechnol. 1996;14:230–234.

    Article  PubMed  CAS  Google Scholar 

  58. Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381:751–758.

    Article  PubMed  CAS  Google Scholar 

  59. Barbas CF, 3rd, Hu D, Dunlop N, et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A. 1994;91:3809–3813.

    Article  PubMed  CAS  Google Scholar 

  60. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol. 1999;17:568–572.

    Article  PubMed  CAS  Google Scholar 

  61. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem. 2005;280:607–617.

    Article  PubMed  CAS  Google Scholar 

  62. Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF, 3rd. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol. 1995;254:392–403.

    Article  PubMed  CAS  Google Scholar 

  63. Schier R, McCall A, Adams GP, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996;263:551–567.

    Article  PubMed  CAS  Google Scholar 

  64. Rader C, Popkov M, Neves JA, Barbas CF, 3rd. Integrin alpha(v)beta3 targeted therapy for Kaposi’s sarcoma with an in vitro evolved antibody. Faseb J. 2002;16:2000–2002.

    PubMed  CAS  Google Scholar 

  65. Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods. 1999;231:249–260.

    Article  PubMed  CAS  Google Scholar 

  66. Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170:3528–3533.

    PubMed  CAS  Google Scholar 

  67. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–6604.

    Article  PubMed  CAS  Google Scholar 

  68. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520–535.

    Article  PubMed  CAS  Google Scholar 

  69. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177–186.

    Article  PubMed  CAS  Google Scholar 

  70. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900–3908.

    PubMed  CAS  Google Scholar 

  71. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol. 1986;16:881–887.

    Article  PubMed  CAS  Google Scholar 

  72. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–2466.

    PubMed  CAS  Google Scholar 

  73. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195.

    PubMed  CAS  Google Scholar 

  74. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833.

    PubMed  CAS  Google Scholar 

  75. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.

    PubMed  CAS  Google Scholar 

  76. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995–1001.

    Article  PubMed  CAS  Google Scholar 

  77. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–3143.

    PubMed  CAS  Google Scholar 

  78. Hainsworth JD, Litchy S, Burris HA, 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261–4267.

    Article  PubMed  CAS  Google Scholar 

  79. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103–1108.

    Article  PubMed  CAS  Google Scholar 

  80. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416–4423.

    Article  PubMed  CAS  Google Scholar 

  81. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–276.

    PubMed  CAS  Google Scholar 

  82. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23:694–704.

    Article  PubMed  CAS  Google Scholar 

  83. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000;27:37–41.

    PubMed  CAS  Google Scholar 

  84. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:389–397.

    PubMed  CAS  Google Scholar 

  85. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.

    Article  PubMed  CAS  Google Scholar 

  86. Feugier P, Van Hoof A, Sebban C, et al. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126.

    Article  PubMed  CAS  Google Scholar 

  87. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927–1932.

    PubMed  CAS  Google Scholar 

  88. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746–1751.

    Article  PubMed  CAS  Google Scholar 

  89. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115–3120.

    Article  PubMed  CAS  Google Scholar 

  90. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53.

    Article  PubMed  CAS  Google Scholar 

  91. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther. 2004;3:361–370.

    PubMed  CAS  Google Scholar 

  92. Witzig TE. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin’s lymphoma. Semin Oncol. 2003;30:11–16.

    Article  PubMed  CAS  Google Scholar 

  93. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med. 2000;27:766–777.

    Article  PubMed  CAS  Google Scholar 

  94. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J Clin Oncol. 2003;21:1263–1270.

    Article  PubMed  CAS  Google Scholar 

  95. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–3803.

    PubMed  CAS  Google Scholar 

  96. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429–4431.

    Article  PubMed  CAS  Google Scholar 

  97. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–3269.

    Article  PubMed  CAS  Google Scholar 

  98. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463.

    Article  PubMed  CAS  Google Scholar 

  99. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266.

    PubMed  CAS  Google Scholar 

  100. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18:1316–1323.

    PubMed  CAS  Google Scholar 

  101. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449.

    Article  PubMed  CAS  Google Scholar 

  102. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712–719.

    Article  PubMed  CAS  Google Scholar 

  103. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351–2357.

    Article  PubMed  CAS  Google Scholar 

  104. Wellhausen SR, Peiper SC. CD33: biochemical and biological characterization and evaluation of clinical relevance. J Biol Regul Homeost Agents. 2002;16:139–143.

    PubMed  CAS  Google Scholar 

  105. Giles FJ. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anticancer Ther. 2002;2:630–640.

    Article  PubMed  CAS  Google Scholar 

  106. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197–3204.

    Article  Google Scholar 

  107. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101:4589–4597.

    Article  PubMed  CAS  Google Scholar 

  108. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254.

    PubMed  CAS  Google Scholar 

  109. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578–1582.

    Article  PubMed  CAS  Google Scholar 

  110. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–1496.

    PubMed  CAS  Google Scholar 

  111. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003;51:87–90.

    Article  PubMed  CAS  Google Scholar 

  112. Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002;50:497–500.

    Article  PubMed  CAS  Google Scholar 

  113. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222–4224.

    Article  PubMed  CAS  Google Scholar 

  114. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431–1439.

    PubMed  CAS  Google Scholar 

  115. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998;95:427–436.

    Article  PubMed  CAS  Google Scholar 

  116. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J Clin Oncol. 1998;16:3257–3263.

    PubMed  CAS  Google Scholar 

  117. Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma. 2002;3:105–110.

    PubMed  CAS  Google Scholar 

  118. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891–3897.

    Article  PubMed  CAS  Google Scholar 

  119. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561.

    Article  PubMed  CAS  Google Scholar 

  120. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93:151–153.

    Article  PubMed  CAS  Google Scholar 

  121. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205–213.

    Article  PubMed  CAS  Google Scholar 

  122. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin’s lymphomas: a multicenter phase I/II study. Ann Hematol. 2002;81:26–32.

    Article  PubMed  CAS  Google Scholar 

  123. Faderl S, Thomas DA, O’Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413–3415.

    Article  PubMed  CAS  Google Scholar 

  124. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245–2247.

    Article  PubMed  CAS  Google Scholar 

  125. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425.

    PubMed  CAS  Google Scholar 

  126. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712.

    Article  PubMed  CAS  Google Scholar 

  127. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.

    Article  PubMed  CAS  Google Scholar 

  128. McKenzie SJ, Marks PJ, Lam T, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene. 1989;4:543–548.

    PubMed  CAS  Google Scholar 

  129. Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991;51:4575–4580.

    PubMed  CAS  Google Scholar 

  130. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726.

    Article  PubMed  CAS  Google Scholar 

  131. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648.

    PubMed  CAS  Google Scholar 

  132. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829–1838.

    PubMed  CAS  Google Scholar 

  133. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–2671.

    PubMed  CAS  Google Scholar 

  134. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587–2595.

    PubMed  CAS  Google Scholar 

  135. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800–1808.

    Article  PubMed  CAS  Google Scholar 

  136. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19:2722–2730.

    PubMed  CAS  Google Scholar 

  137. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.

    Article  PubMed  CAS  Google Scholar 

  138. Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol. 2004;31:51–57.

    Article  PubMed  CAS  Google Scholar 

  139. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36:748–753.

    Article  PubMed  CAS  Google Scholar 

  140. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65.

    Article  PubMed  CAS  Google Scholar 

  141. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  142. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–3508.

    Article  PubMed  CAS  Google Scholar 

  143. Giantonio BJ PC, NJ Meropol, PJ O’Dwyer, EP Mitchell, SR Alberts, MA Schwartz, AB Benson. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol Abstract #2; 2005.

    Google Scholar 

  144. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191.

    Article  PubMed  CAS  Google Scholar 

  145. Sandler AB RG, J Brahmer, A Dowlati, JH Schiller, MC Perry, DH Johnson. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Onc (Abstract No: LBA4); 2005.

    Google Scholar 

  146. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434.

    Article  PubMed  CAS  Google Scholar 

  147. Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs. 2002;11:755–768.

    Article  PubMed  CAS  Google Scholar 

  148. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37 Suppl 4:S9–15.

    Article  PubMed  CAS  Google Scholar 

  149. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999;5:909–916.

    PubMed  CAS  Google Scholar 

  150. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti–epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234–3243.

    PubMed  CAS  Google Scholar 

  151. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208.

    Article  PubMed  CAS  Google Scholar 

  152. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345.

    Article  PubMed  CAS  Google Scholar 

  153. Díaz Rubio E JT, E van Cutsem, A Cervantes, T André, Y Humblet, P Soulié, S Corretgé, O Kisker, A de Gramont. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Am Soc Clin Oncol (Abstract No: 3535); 2005.

    Google Scholar 

  154. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003;21:99–101.

    Article  PubMed  CAS  Google Scholar 

  155. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004;22:2610–2616.

    Article  PubMed  CAS  Google Scholar 

  156. Adkins JC, Spencer CM. Edrecolomab (monoclonal antibody 17–1A). Drugs. 1998;56:619–626; discussion 627–618.

    Article  PubMed  CAS  Google Scholar 

  157. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788–1794.

    PubMed  CAS  Google Scholar 

  158. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360:671–677.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Christoph Rader & Michael R. Bishop

Authors
  1. Christoph Rader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R. Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY

    Howard L. Kaufman

  2. Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY

    Jedd D. Wolchok

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Rader, C., Bishop, M.R. (2007). Monoclonal Antibodies in Cancer Therapy. In: Kaufman, H.L., Wolchok, J.D. (eds) General Principles of Tumor Immunotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6087-8_20

Download citation

Publish with us

Policies and ethics

Search

Navigation